Relmada Therapeutics (RLMD) Competitors $0.37 -0.01 (-1.66%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends RLMD vs. DYAI, ICCC, ACHL, TNXP, IVVD, ELEV, XLO, KZR, CELU, and VYNEShould you be buying Relmada Therapeutics stock or one of its competitors? The main competitors of Relmada Therapeutics include Dyadic International (DYAI), ImmuCell (ICCC), Achilles Therapeutics (ACHL), Tonix Pharmaceuticals (TNXP), Invivyd (IVVD), Elevation Oncology (ELEV), Xilio Therapeutics (XLO), Kezar Life Sciences (KZR), Celularity (CELU), and VYNE Therapeutics (VYNE). These companies are all part of the "pharmaceutical products" industry. Relmada Therapeutics vs. Dyadic International ImmuCell Achilles Therapeutics Tonix Pharmaceuticals Invivyd Elevation Oncology Xilio Therapeutics Kezar Life Sciences Celularity VYNE Therapeutics Dyadic International (NASDAQ:DYAI) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends. Do insiders & institutionals have more ownership in DYAI or RLMD? 28.0% of Dyadic International shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 28.8% of Dyadic International shares are held by company insiders. Comparatively, 18.0% of Relmada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media prefer DYAI or RLMD? In the previous week, Dyadic International's average media sentiment score of 1.00 beat Relmada Therapeutics' score of 0.00 indicating that Dyadic International is being referred to more favorably in the media. Company Overall Sentiment Dyadic International Positive Relmada Therapeutics Neutral Do analysts rate DYAI or RLMD? Dyadic International currently has a consensus target price of $6.00, indicating a potential upside of 300.00%. Relmada Therapeutics has a consensus target price of $4.25, indicating a potential upside of 1,036.97%. Given Relmada Therapeutics' higher possible upside, analysts plainly believe Relmada Therapeutics is more favorable than Dyadic International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyadic International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Relmada Therapeutics 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is DYAI or RLMD more profitable? Relmada Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -188.09%. Relmada Therapeutics' return on equity of -129.80% beat Dyadic International's return on equity.Company Net Margins Return on Equity Return on Assets Dyadic International-188.09% -149.16% -59.81% Relmada Therapeutics N/A -129.80%-112.06% Which has more risk & volatility, DYAI or RLMD? Dyadic International has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Which has better earnings & valuation, DYAI or RLMD? Dyadic International has higher revenue and earnings than Relmada Therapeutics. Dyadic International is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyadic International$3.36M13.19-$6.80M-$0.23-6.52Relmada TherapeuticsN/AN/A-$98.79M-$2.87-0.13 Does the MarketBeat Community favor DYAI or RLMD? Dyadic International received 144 more outperform votes than Relmada Therapeutics when rated by MarketBeat users. Likewise, 64.40% of users gave Dyadic International an outperform vote while only 37.78% of users gave Relmada Therapeutics an outperform vote. CompanyUnderperformOutperformDyadic InternationalOutperform Votes16164.40% Underperform Votes8935.60% Relmada TherapeuticsOutperform Votes1737.78% Underperform Votes2862.22% SummaryDyadic International beats Relmada Therapeutics on 10 of the 15 factors compared between the two stocks. Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLMD vs. The Competition Export to ExcelMetricRelmada TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.28M$6.22B$5.21B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E Ratio-0.139.9189.4217.36Price / SalesN/A309.211,240.0477.11Price / CashN/A61.4443.7535.97Price / Book0.136.055.314.79Net Income-$98.79M$154.90M$122.54M$225.00M7 Day Performance-6.57%1.35%1.42%2.37%1 Month Performance3.00%0.41%2.51%4.40%1 Year Performance-89.13%3.08%25.29%20.10% Relmada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLMDRelmada Therapeutics4.046 of 5 stars$0.37-1.7%$4.25+1,037.0%-89.1%$11.28MN/A-0.1310Gap UpDYAIDyadic International3.1532 of 5 stars$1.61-2.4%$6.00+272.7%-3.8%$47.64M$3.36M-7.007Positive NewsGap UpICCCImmuCell0.1064 of 5 stars$5.33+2.7%N/A+3.7%$47.50M$23.84M-10.6670ACHLAchilles Therapeutics2.6883 of 5 stars$1.15-3.0%$4.00+247.8%+38.6%$47.27MN/A-0.70250Positive NewsTNXPTonix Pharmaceuticals3.0931 of 5 stars$0.25-9.3%$53.50+21,071.3%-97.4%$47.23M$11.29M0.0050Gap DownIVVDInvivyd3.0895 of 5 stars$0.39-12.9%$7.89+1,902.4%-91.4%$47.12M$11.56M-0.20100Short Interest ↑ELEVElevation Oncology2.6227 of 5 stars$0.79+21.4%$7.20+812.2%-71.9%$46.66MN/A-0.9640Gap UpHigh Trading VolumeXLOXilio Therapeutics3.205 of 5 stars$1.06-3.6%$4.00+277.4%+67.9%$46.60M$4.62M-0.6270Positive NewsKZRKezar Life Sciences3.9188 of 5 stars$6.30-3.2%$39.50+527.0%-25.4%$45.97M$7M-0.4860CELUCelularity0.3711 of 5 stars$2.09-3.2%N/A-21.8%$45.95M$48.20M0.00220Short Interest ↑Negative NewsGap DownVYNEVYNE Therapeutics3.8125 of 5 stars$3.10-9.6%$6.88+121.8%+51.7%$45.73M$493,000.00-3.6030Gap Up Related Companies and Tools Related Companies Dyadic International Alternatives ImmuCell Alternatives Achilles Therapeutics Alternatives Tonix Pharmaceuticals Alternatives Invivyd Alternatives Elevation Oncology Alternatives Xilio Therapeutics Alternatives Kezar Life Sciences Alternatives Celularity Alternatives VYNE Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RLMD) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RLMD Stock Alerts